Document is current
Any future updates will be listed below
-
Authors
Gabrielsen, Endre
Wilsgaard, Tom
Frydenberg, Hanne
Lofterød, Trygve
Dalen, Stig Manfred
Mortensen, Elin
Solbu, Marit D.
Nalwoga, Hawa
Akslen, Lars A.
Blix, Egil S.
Haugnes, Hege S.
-
Funding
Funding for this research was provided by:
The Northern Norway Regional Health Authority (HNF1529-20)
UiT The Arctic University of Norway
- License Information
-
More Information
Article History
Received: 30 May 2025
Accepted: 13 July 2025
First Online: 22 July 2025
Declarations
:
: ESB: has received honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer and Roche. HSH: has received honoraria from Merck, Janssen-Cilag, and Bayer. MDS: has received honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, and Vifor Pharma Other authors report no conflicts of interest.
: The EBBA-life study has been approved by the Regional Committee for Medical and Health Research Ethics (REK) (2015/599). The Tromsø Study has been approved by REK (2014/940), Norwegian Data Protection Authority (14/01463–8/CGN September 07, 2015) and the Data Protection Impact Assessment (DPIA) (379273).
: A declaration of consent was signed by all participants when enrolled in the Tromsø5 Study.
: Not applicable, as no identifiable individual data are included in this study.
